ArticleJournal of the American Chemical Society2026
A General Photoredox Platform for the Hydroarylation of Olefins.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Alkene hydroarylation provides a direct strategy for merging aryl groups with alkene-derived C(sp3)-rich fragments, yet general methods that employ abundant aryl bromides across diverse alkene classes remain elusive. Herein, we report XAT-Heck, a radical hydroarylation platform that couples aryl bromides with alkenes under mild photoredox conditions through halogen-atom transfer (XAT)-enabled aryl radical generation. The method accommodates terminal, internal, and gem-disubstituted alkenes, as well as a broad range of heteroaryl and aryl bromides. Chemical-space mapping further supports the broad coverage of commercially available olefin and aryl bromide space. The versatility of this platform is showcased through deuterium incorporation, medium-ring formation, late-stage functionalization, and proteolysis-targeting chimera (PROTAC) library construction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.